FDA’s Class I recall record for Tandem Mobi describes a problem in which increased friction in the drive mechanism can trigger an occlusion alarm and interrupt insulin delivery. The record identifies the company’s action as beginning on 23 September 2026; FDA posted the entry on 30 October. It is listed as open and classified in the record checked for this article. FDA event record

The important reading task is to separate the reported mechanism, the listed devices and the official response. The existence of a false-alarm problem does not establish that a particular person’s alarm is false.

The mechanism concerns the pump’s response to resistance

The FDA entry describes increased drive-module friction that reduces motor performance below the threshold used to trigger an occlusion alarm. Such an alarm suspends delivery until the user acknowledges it and resumes delivery as described in the record. Repeated interruption can create a risk of high blood glucose. Recorded reason for correction

That account explains why an alarm can matter even when the reported fault is described as “false occlusion.” The word “false” refers to the identified triggering problem; it is not permission to ignore an alarm or a way to determine remotely whether there is an actual obstruction.

This article does not provide a replacement pump procedure or instructions for changing insulin delivery. Current device instructions and the manufacturer’s correction process govern the relevant device-specific steps; individual treatment questions belong with the person’s care team.

Dates and identifiers serve different purposes

Dates and identifiers serve different purposes
Detail in the official recordWhy it matters
Firm initiation: 23 September 2026Identifies when the company’s recorded action began.
FDA posting: 30 October 2026Identifies the public database entry date, not a new fault beginning that day.
Recall number Z-0316-2027Identifies this specific recall record.
Model and UDI informationSupports checking the scope against a particular device through the official process.

The entry lists 80,938 units in commerce across the US and Canada. That is a distribution quantity, not a count of affected patients, confirmed failures or injuries. Dividing an unrelated report count by that quantity would not automatically produce a valid patient-risk estimate. Dates, identifiers and quantity

Class I describes seriousness, not frequency

FDA defines Class I as a situation with a reasonable chance of serious health problems or death. The classification expresses the seriousness of the potential hazard; it does not supply the probability that a particular unit will fail or that a particular user will be harmed. FDA recall explanation

The same explanation distinguishes a correction performed where a device is used from a removal. “Recall” covers both kinds of action. It does not always mean every user must stop using or return the device. The specific notice and instructions therefore matter more than an assumption drawn from the general word.

Keep the current official process close to the device

The event entry reproduces customer communications, including following the user guide and contacting Tandem support for unusual or persistent alarms or disrupted therapy. Readers checking a device should use the identifiers and contact route in that official record, rather than infer eligibility or a remedy from a news headline. Official scope and customer-action account

FDA explains that its database is updated as recalls are classified and later terminated. A saved article is therefore a dated account, while the recall database is the place to check for a later status.

Our medical-device surveillance explainer considers the broader reporting system in another jurisdiction. This US event illustrates why distribution, a reported mechanism, regulatory classification and an individual device decision must retain their own meanings.